[go: up one dir, main page]

AU2001294890A1 - Pei: dna vector formulations for in vitro and in vivo gene delivery - Google Patents

Pei: dna vector formulations for in vitro and in vivo gene delivery

Info

Publication number
AU2001294890A1
AU2001294890A1 AU2001294890A AU9489001A AU2001294890A1 AU 2001294890 A1 AU2001294890 A1 AU 2001294890A1 AU 2001294890 A AU2001294890 A AU 2001294890A AU 9489001 A AU9489001 A AU 9489001A AU 2001294890 A1 AU2001294890 A1 AU 2001294890A1
Authority
AU
Australia
Prior art keywords
pei
vitro
gene delivery
dna vector
vivo gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294890A
Inventor
Richard J. Cristiano
Motoyuki Yamashita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU2001294890A1 publication Critical patent/AU2001294890A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001294890A 2000-09-25 2001-09-25 Pei: dna vector formulations for in vitro and in vivo gene delivery Abandoned AU2001294890A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23523700P 2000-09-25 2000-09-25
US60/235,237 2000-09-25
US23563500P 2000-09-26 2000-09-26
US60/235,635 2000-09-26
PCT/US2001/030503 WO2002024232A2 (en) 2000-09-25 2001-09-25 Pei: dna vector formulations for in vitro and in vivo gene delivery

Publications (1)

Publication Number Publication Date
AU2001294890A1 true AU2001294890A1 (en) 2002-04-02

Family

ID=26928714

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294890A Abandoned AU2001294890A1 (en) 2000-09-25 2001-09-25 Pei: dna vector formulations for in vitro and in vivo gene delivery

Country Status (5)

Country Link
US (1) US6846809B2 (en)
EP (1) EP1322337A2 (en)
AU (1) AU2001294890A1 (en)
CA (1) CA2422524A1 (en)
WO (1) WO2002024232A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004537501A (en) * 2001-02-01 2004-12-16 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム Stabilized polymer aerosol for gene delivery to the lung
DE10131145B4 (en) * 2001-06-28 2005-07-14 Innovent E.V. Composition for cell-specific transfer of active ingredients
FR2826869A1 (en) * 2001-07-04 2003-01-10 Ct Regional De Lutte Contre Le PRODUCTS SUITABLE TO TREAT OVARIAN CANCERS AND PREVENT RELAPSES
US7153905B2 (en) * 2003-03-21 2006-12-26 The General Hospital Corporation Hyperbranched dendron and methods of synthesis and use thereof
EP1616957B1 (en) * 2003-04-18 2017-05-17 National Cerebral and Cardiovascular Center Vector
CN1889963A (en) * 2003-10-10 2007-01-03 宝德杰克特疫苗有限公司 Method
US7740861B2 (en) * 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
US20060040879A1 (en) * 2004-08-21 2006-02-23 Kosak Kenneth M Chloroquine coupled nucleic acids and methods for their synthesis
KR20070054246A (en) 2004-09-17 2007-05-28 유니버시티 오브 매사추세츠 Compositions for their lysosomal enzyme deficiency and uses thereof
US7723570B2 (en) 2004-10-12 2010-05-25 Soymeds, Inc. Edible vaccines expressed in soybeans
WO2007050643A2 (en) * 2005-10-24 2007-05-03 University Of Massachusetts Compositions and their uses for gene therapy of bone conditions
US9303080B2 (en) 2006-01-13 2016-04-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
US20080108513A1 (en) * 2006-06-01 2008-05-08 Northwestern University Cellular Arrays
US20100021379A1 (en) * 2006-06-29 2010-01-28 The Regents Of The University Of California Chemical Antibodies for Immunotherapy and Imaging
US20080145893A1 (en) * 2006-09-17 2008-06-19 Excellegene Sa Method for producing a recombinant protein at high specific productivity, high batch yield and high volumetric yield by means of transient transfection
CN101627123A (en) * 2007-01-08 2010-01-13 米利波尔公司 High expression cell line that eliminates gene amplification
CA2682161A1 (en) 2007-03-29 2008-10-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from ebola virus
WO2008128251A1 (en) * 2007-04-17 2008-10-23 The Children's Hospital Of Philadelphia Humanized viral vectors and methods of use thereof
US20080312174A1 (en) * 2007-06-05 2008-12-18 Nitto Denko Corporation Water soluble crosslinked polymers
CA2704056A1 (en) * 2007-10-29 2009-05-07 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
US20100285111A1 (en) * 2007-11-09 2010-11-11 Northeastern University Self-assembling micelle-like nanoparticles for systemic gene delivery
EP2242520A2 (en) * 2008-01-14 2010-10-27 SurModics, Inc. Devices and methods for elution of nucleic acid delivery complexes
US8344116B2 (en) * 2008-03-17 2013-01-01 Case Western Reserve University Polymers and complexes for delivery of nucleic acids to intracellular targets
CA2723192A1 (en) * 2008-05-07 2009-11-12 Surmodics, Inc. Delivery of nucleic acid complexes from particles
US9029338B2 (en) * 2009-08-14 2015-05-12 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US20110159098A1 (en) * 2009-12-30 2011-06-30 Surmodics, Inc. Stabilization and delivery of nucleic acid complexes
CN102811746A (en) * 2010-01-18 2012-12-05 得克萨斯系统大学评议会 Methods and compositions for nanoparticle-mediated targeted delivery of cancer cells
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins PROLONGED DELIVERY OF THERAPEUTIC AGENTS TO AN OCULAR COMPARTMENT
US20130052221A1 (en) 2010-02-26 2013-02-28 The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services Dna-protein vaccination protocols
TWI415940B (en) 2010-12-20 2013-11-21 Univ Kaohsiung Medical Hybrid superparamagnetic iron oxide nanoparticles and polyethylenimine as a magnetoplex for gene transfection
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
CA2826171C (en) 2011-02-07 2018-05-22 Innovative Surface Technologies, Inc. Neural transfection reagents
US9327037B2 (en) * 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US10335500B2 (en) 2014-05-12 2019-07-02 The Johns Hopkins University Highly stable biodegradable gene vector platforms for overcoming biological barriers
EP3250184B1 (en) 2015-01-27 2024-12-18 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
WO2020210805A1 (en) 2019-04-11 2020-10-15 The Johns Hopkins University Nanoparticles for drug delivery to brain

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5149543A (en) * 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
US5260002A (en) * 1991-12-23 1993-11-09 Vanderbilt University Method and apparatus for producing uniform polymeric spheres
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US5972600A (en) * 1992-04-03 1999-10-26 The Regents Of The University Of California Separation of active complexes
US5641656A (en) * 1993-10-22 1997-06-24 University Of Connecticut Nucleic acids encoding avian interferon (IFN) proteins and recombinant methods using them
US5824654A (en) * 1994-09-02 1998-10-20 New York University Method for delivery of nucleic acids to cells using hypericin polyamine complexes
DE69520044T2 (en) * 1994-10-12 2001-06-13 Focal, Inc. TARGETED ADMINISTRATION USING BIODEGRADABLE POLYMERS
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
WO1996015811A1 (en) * 1994-11-17 1996-05-30 Imperial College Of Science, Technology & Medicine Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand
US5656611A (en) 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US5656615A (en) * 1995-04-12 1997-08-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers and viruses in mammals
US5908777A (en) * 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
US6071741A (en) * 1995-10-12 2000-06-06 General Hospital Corporation Doc tumor suppressor protein and gene
CA2271325A1 (en) * 1996-11-12 1998-05-22 The Regents Of The University Of California Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
DE19726186A1 (en) * 1997-06-20 1998-12-24 Boehringer Ingelheim Int Complexes for the transport of nucleic acid into higher eukaryotic cells
US6383811B2 (en) * 1997-12-30 2002-05-07 Mirus Corporation Polyampholytes for delivering polyions to a cell
WO1999042091A2 (en) * 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Use of polycations as endosomolytic agents
US6281005B1 (en) * 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
NZ516641A (en) * 1999-07-23 2003-07-25 Genentech Inc Method for RNase- and organic solvent-free plasmid DNA purification using tangential flow filtration

Also Published As

Publication number Publication date
WO2002024232A3 (en) 2003-01-30
US6846809B2 (en) 2005-01-25
CA2422524A1 (en) 2002-03-28
WO2002024232A2 (en) 2002-03-28
EP1322337A2 (en) 2003-07-02
US20020151060A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
AU2001294890A1 (en) Pei: dna vector formulations for in vitro and in vivo gene delivery
EP1594883A4 (en) Covalent modification of rna for in vitro and in vivo delivery
AU2001270300A1 (en) Drug delivery formulations and targeting
AU6097100A (en) Crosslinked dna condensate compositions and gene delivery methods
AU2002305346A1 (en) Techniques and compositions for treating cardiovascular disease by (in vivo) gene delivery
AU2001285047A1 (en) Human genes and gene expression products
AU2001245619A1 (en) Human genes and gene expression products
AU9692198A (en) Gene delivery compositions and methods
AU2001264166A1 (en) Vector constructs
GB0012997D0 (en) Gene delivery
AU2001257532A1 (en) Adenoviral vectors for tumor specific gene expression and uses thereof
AU2001245987A1 (en) Compositions and methods for gene therapy
AU2001238485A1 (en) Methods and compositions for gene delivery
AU2002365188A1 (en) Nucleic acid delivery and expression
AU2002356898A1 (en) Gene amplification and overexpression in cancer
AU2002306461A1 (en) In vivo delivery methods and compositions
AU7954500A (en) Method of in vitro culture of lymphocytes and gene therapy compositions
AU2001270478A1 (en) Gene expression in biological conditions
AU6094200A (en) Nor gene compositions and methods for use thereof
AU5474400A (en) Compositions and methods for targeted gene insertion
AU2153401A (en) Gene expression in biological conditions
AU2001259174A1 (en) Viral and non-viral vectors as vehicles for delivering transgenes for treating bone pathologies
AU2001266189A1 (en) Materials and methods relating to gene delivery
AU6919300A (en) Methods for in vivo gene delivery to sites of cartilage damage
AU5617200A (en) Nodavirus-based dna expression vector and uses thereof